NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS/MND and Parkinson’s Gallery

Complement Therapeutics Announces FDA Fast Track Designation for CTx001 for the Treatment of Geographic Atrophy Secondary to AMD Gallery

TauC3 Biologics secures $2.5 million to advance novel treatment approach for neurodegenerative disease Gallery

Unravel Health joins SBC to drive innovation in women’s hormonal health Gallery

SymphoRNA establishes presence at SBC to advance next generation RNA therapeutics Gallery

Anomer Bio arrives at SBC to develop a new class of glycan-targeting therapeutics Gallery

SBC welcomes ‘virtual scientists’ in first-of-its-kind AI partnership to speed UK biotech innovation Gallery

A warm welcome to LifeArc’s new Industrial Placement (IP) students Gallery

Santo Therapeutics Raises Multi-Million (GBP-Equivalent) Round Led by FIRHealth Capital Gallery

Complement Therapeutics Receives FDA IND Clearance to Advance CTx001 into Opti-GAIN, a Phase I/II Clinical Trial in Geographic Atrophy secondary to AMD Gallery

Aerska, a biotech focused on neurological disease, has chosen SBC as its UK base of lab operations Gallery

Neobe Therapeutics wins Pathfinder 2025 at Business Weekly 35th Anniversary Awards Gallery

NRG Therapeutics Announces £50m Series B Financing to Deliver Clinical Data in Parkinson’s and ALS/MND Gallery

Welcome RosettaPath to SBC’s Seed Works office! Gallery

PhD Student Opportunity at Entoplast Gallery

First non-hormonal menopause treatment approved for use in the UK by the MHRA, with early-stage development at Stevenage Bioscience Catalyst Gallery

Job Vacancy: Part-Time Interim Finance Manager Gallery

Five SBC companies shortlisted for Business Weekly Awards! Gallery

Five new positions open for application at Autifony Therapeutics! Gallery

A Sunny SBC Summer Party at Last! Gallery